1. Home
  2. CRSP vs BBAR Comparison

CRSP vs BBAR Comparison

Compare CRSP & BBAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • BBAR
  • Stock Information
  • Founded
  • CRSP 2013
  • BBAR 1886
  • Country
  • CRSP Switzerland
  • BBAR Argentina
  • Employees
  • CRSP N/A
  • BBAR N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • BBAR Commercial Banks
  • Sector
  • CRSP Health Care
  • BBAR Finance
  • Exchange
  • CRSP Nasdaq
  • BBAR Nasdaq
  • Market Cap
  • CRSP 3.4B
  • BBAR 3.9B
  • IPO Year
  • CRSP 2016
  • BBAR N/A
  • Fundamental
  • Price
  • CRSP $36.99
  • BBAR $18.70
  • Analyst Decision
  • CRSP Buy
  • BBAR Buy
  • Analyst Count
  • CRSP 19
  • BBAR 1
  • Target Price
  • CRSP $74.35
  • BBAR $27.00
  • AVG Volume (30 Days)
  • CRSP 1.6M
  • BBAR 599.9K
  • Earning Date
  • CRSP 05-07-2025
  • BBAR 03-05-2025
  • Dividend Yield
  • CRSP N/A
  • BBAR 7.65%
  • EPS Growth
  • CRSP N/A
  • BBAR N/A
  • EPS
  • CRSP N/A
  • BBAR 0.56
  • Revenue
  • CRSP $37,314,000.00
  • BBAR $3,440,514,989.00
  • Revenue This Year
  • CRSP $49.76
  • BBAR N/A
  • Revenue Next Year
  • CRSP $257.28
  • BBAR N/A
  • P/E Ratio
  • CRSP N/A
  • BBAR $13.75
  • Revenue Growth
  • CRSP N/A
  • BBAR N/A
  • 52 Week Low
  • CRSP $36.52
  • BBAR $7.05
  • 52 Week High
  • CRSP $68.39
  • BBAR $25.01
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 34.31
  • BBAR 47.65
  • Support Level
  • CRSP $40.41
  • BBAR $18.06
  • Resistance Level
  • CRSP $42.72
  • BBAR $20.41
  • Average True Range (ATR)
  • CRSP 1.73
  • BBAR 1.01
  • MACD
  • CRSP -0.55
  • BBAR 0.16
  • Stochastic Oscillator
  • CRSP 0.80
  • BBAR 51.97

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About BBAR Banco BBVA Argentina S.A. ADS

Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focused on foreign trade, agricultural business, and digital products.

Share on Social Networks: